ID   TRI32_HUMAN             Reviewed;         653 AA.
AC   Q13049; Q9NQP8;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2002, sequence version 2.
DT   10-MAY-2017, entry version 187.
DE   RecName: Full=E3 ubiquitin-protein ligase TRIM32;
DE            EC=2.3.2.27;
DE   AltName: Full=72 kDa Tat-interacting protein;
DE   AltName: Full=RING-type E3 ubiquitin transferase TRIM32 {ECO:0000305};
DE   AltName: Full=Tripartite motif-containing protein 32;
DE   AltName: Full=Zinc finger protein HT2A;
GN   Name=TRIM32; Synonyms=HT2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7778269; DOI=10.1006/viro.1995.1266;
RA   Fridell R.A., Harding L.S., Bogerd H.P., Cullen B.R.;
RT   "Identification of a novel human zinc finger protein that specifically
RT   interacts with the activation domain of lentiviral Tat proteins.";
RL   Virology 209:347-357(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 2-15; 51-60; 70-101; 205-238; 248-282; 345-359;
RP   467-500; 587-596 AND 605-613, CLEAVAGE OF INITIATOR METHIONINE,
RP   ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [6]
RP   FUNCTION AS AN E3 UBIQUITIN-PROTEIN LIGASE, UBIQUITINATION,
RP   SELF-ASSOCIATION, AND INTERACTION WITH DTNBP1.
RX   PubMed=19349376; DOI=10.1093/hmg/ddp167;
RA   Locke M., Tinsley C.L., Benson M.A., Blake D.J.;
RT   "TRIM32 is an E3 ubiquitin ligase for dysbindin.";
RL   Hum. Mol. Genet. 18:2344-2358(2009).
RN   [7]
RP   FUNCTION.
RX   PubMed=22500027; DOI=10.1074/jbc.M112.341487;
RA   Zhang Q., Yu D., Seo S., Stone E.M., Sheffield V.C.;
RT   "Intrinsic protein-protein interaction-mediated and chaperonin-
RT   assisted sequential assembly of stable Bardet-Biedl syndrome protein
RT   complex, the BBSome.";
RL   J. Biol. Chem. 287:20625-20635(2012).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-335 AND SER-339, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9]
RP   STRUCTURE BY NMR OF 10-84.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the RING domain of the tripartite motif protein
RT   32.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [10]
RP   VARIANT LGMD2H ASN-487, AND TISSUE SPECIFICITY.
RX   PubMed=11822024; DOI=10.1086/339083;
RA   Frosk P., Weiler T., Nylen E., Sudha T., Greenberg C.R., Morgan K.,
RA   Fujiwara T.M., Wrogemann K.;
RT   "Limb-girdle muscular dystrophy type 2H associated with mutation in
RT   TRIM32, a putative E3-ubiquitin-ligase gene.";
RL   Am. J. Hum. Genet. 70:663-672(2002).
RN   [11]
RP   VARIANT BBS11 SER-130.
RX   PubMed=16606853; DOI=10.1073/pnas.0600158103;
RA   Chiang A.P., Beck J.S., Yen H.-J., Tayeh M.K., Scheetz T.E.,
RA   Swiderski R.E., Nishimura D.Y., Braun T.A., Kim K.-Y.A., Huang J.,
RA   Elbedour K., Carmi R., Slusarski D.C., Casavant T.L., Stone E.M.,
RA   Sheffield V.C.;
RT   "Homozygosity mapping with SNP arrays identifies TRIM32, an E3
RT   ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS11).";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6287-6292(2006).
RN   [12]
RP   VARIANTS LGMD2H HIS-394 AND ASP-588 DEL.
RX   PubMed=17994549; DOI=10.1002/humu.20633;
RA   Saccone V., Palmieri M., Passamano L., Piluso G., Meroni G.,
RA   Politano L., Nigro V.;
RT   "Mutations that impair interaction properties of TRIM32 associated
RT   with limb-girdle muscular dystrophy 2H.";
RL   Hum. Mutat. 29:240-247(2008).
RN   [13]
RP   VARIANT GLN-299.
RX   PubMed=21344540; DOI=10.1002/humu.21480;
RA   Deveault C., Billingsley G., Duncan J.L., Bin J., Theal R.,
RA   Vincent A., Fieggen K.J., Gerth C., Noordeh N., Traboulsi E.I.,
RA   Fishman G.A., Chitayat D., Knueppel T., Millan J.M., Munier F.L.,
RA   Kennedy D., Jacobson S.G., Innes A.M., Mitchell G.A., Boycott K.,
RA   Heon E.;
RT   "BBS genotype-phenotype assessment of a multiethnic patient cohort
RT   calls for a revision of the disease definition.";
RL   Hum. Mutat. 32:610-619(2011).
CC   -!- FUNCTION: Has an E3 ubiquitin ligase activity. Ubiquitinates
CC       DTNBP1 (dysbindin) and promotes its degradation. May ubiquitinate
CC       BBS2. May play a significant role in mediating the biological
CC       activity of the HIV-1 Tat protein in vivo. Binds specifically to
CC       the activation domain of HIV-1 Tat and can also interact with the
CC       HIV-2 and EIAV Tat proteins in vivo. {ECO:0000269|PubMed:19349376,
CC       ECO:0000269|PubMed:22500027}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with DTNBP1. It self-associates.
CC       {ECO:0000269|PubMed:19349376}.
CC   -!- INTERACTION:
CC       Self; NbExp=4; IntAct=EBI-742790, EBI-742790;
CC       B3KPU6:-; NbExp=3; IntAct=EBI-742790, EBI-10175879;
CC       Q9NYB9:ABI2; NbExp=3; IntAct=EBI-742790, EBI-743598;
CC       Q9NYB9-2:ABI2; NbExp=6; IntAct=EBI-742790, EBI-11096309;
CC       P54253:ATXN1; NbExp=2; IntAct=EBI-742790, EBI-930964;
CC       Q8N3C7:CLIP4; NbExp=5; IntAct=EBI-742790, EBI-5655540;
CC       Q99J34:Irak1 (xeno); NbExp=2; IntAct=EBI-742790, EBI-6117042;
CC       Q7L273:KCTD9; NbExp=5; IntAct=EBI-742790, EBI-4397613;
CC       O76083:PDE9A; NbExp=6; IntAct=EBI-742790, EBI-742764;
CC       O76083-2:PDE9A; NbExp=8; IntAct=EBI-742790, EBI-11524542;
CC       Q06124:PTPN11; NbExp=3; IntAct=EBI-742790, EBI-297779;
CC       Q9UI14:RABAC1; NbExp=9; IntAct=EBI-742790, EBI-712367;
CC       P11684:SCGB1A1; NbExp=6; IntAct=EBI-742790, EBI-7797649;
CC       O00560:SDCBP; NbExp=5; IntAct=EBI-742790, EBI-727004;
CC       Q5T7P8-2:SYT6; NbExp=5; IntAct=EBI-742790, EBI-10246152;
CC       Q9C035:TRIM5; NbExp=2; IntAct=EBI-742790, EBI-924214;
CC       P61088:UBE2N; NbExp=3; IntAct=EBI-742790, EBI-1052908;
CC       Q5VVX9:UBE2U; NbExp=4; IntAct=EBI-742790, EBI-2130181;
CC       Q13404:UBE2V1; NbExp=3; IntAct=EBI-742790, EBI-1050671;
CC       Q9UMX0:UBQLN1; NbExp=8; IntAct=EBI-742790, EBI-741480;
CC       Q9UMX0-2:UBQLN1; NbExp=3; IntAct=EBI-742790, EBI-10173939;
CC       Q9UHD9:UBQLN2; NbExp=4; IntAct=EBI-742790, EBI-947187;
CC       Q9NRR5:UBQLN4; NbExp=3; IntAct=EBI-742790, EBI-711226;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Note=Localized in cytoplasmic
CC       bodies, often located around the nucleus.
CC   -!- TISSUE SPECIFICITY: Spleen, thymus, prostate, testis, ovary,
CC       intestine, colon and skeletal muscle.
CC       {ECO:0000269|PubMed:11822024}.
CC   -!- PTM: Ubiquitinated. {ECO:0000269|PubMed:19349376}.
CC   -!- DISEASE: Limb-girdle muscular dystrophy 2H (LGMD2H) [MIM:254110]:
CC       An autosomal recessive degenerative myopathy characterized by
CC       pelvic girdle, shoulder girdle and quadriceps muscle weakness.
CC       Clinical phenotype and severity are highly variable. Disease
CC       progression is slow and most patients remain ambulatory into the
CC       sixth decade of life. {ECO:0000269|PubMed:11822024,
CC       ECO:0000269|PubMed:17994549}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Bardet-Biedl syndrome 11 (BBS11) [MIM:615988]: A syndrome
CC       characterized by usually severe pigmentary retinopathy, early-
CC       onset obesity, polydactyly, hypogenitalism, renal malformation and
CC       mental retardation. Secondary features include diabetes mellitus,
CC       hypertension and congenital heart disease. Bardet-Biedl syndrome
CC       inheritance is autosomal recessive, but three mutated alleles (two
CC       at one locus, and a third at a second locus) may be required for
CC       clinical manifestation of some forms of the disease.
CC       {ECO:0000269|PubMed:16606853}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. It has
CC       been suggested that TRIM32 might be the E3 ubiquitin ligase for
CC       BBS2, a component of the BBSome complex involved in ciliogenesis,
CC       that is ubiquitinated and degraded by the proteasome
CC       (PubMed:22500027). {ECO:0000269|PubMed:22500027}.
CC   -!- SIMILARITY: Belongs to the TRIM/RBCC family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Leiden Muscular Dystrophy pages; Note=TRIM32;
CC       URL="http://www.dmd.nl/trim32_home.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U18543; AAA86474.1; -; mRNA.
DR   EMBL; AL133284; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC003154; AAH03154.1; -; mRNA.
DR   CCDS; CCDS6817.1; -.
DR   RefSeq; NP_001093149.1; NM_001099679.1.
DR   RefSeq; NP_036342.2; NM_012210.3.
DR   RefSeq; XP_005251870.1; XM_005251813.3.
DR   RefSeq; XP_011516700.1; XM_011518398.2.
DR   RefSeq; XP_016869975.1; XM_017014486.1.
DR   UniGene; Hs.591910; -.
DR   PDB; 2CT2; NMR; -; A=10-84.
DR   PDB; 5FEY; X-ray; 2.23 A; A/B=7-93.
DR   PDBsum; 2CT2; -.
DR   PDBsum; 5FEY; -.
DR   ProteinModelPortal; Q13049; -.
DR   SMR; Q13049; -.
DR   BioGrid; 116608; 81.
DR   IntAct; Q13049; 50.
DR   MINT; MINT-2854880; -.
DR   STRING; 9606.ENSP00000363095; -.
DR   iPTMnet; Q13049; -.
DR   PhosphoSitePlus; Q13049; -.
DR   BioMuta; TRIM32; -.
DR   DMDM; 20178303; -.
DR   EPD; Q13049; -.
DR   MaxQB; Q13049; -.
DR   PaxDb; Q13049; -.
DR   PeptideAtlas; Q13049; -.
DR   PRIDE; Q13049; -.
DR   DNASU; 22954; -.
DR   Ensembl; ENST00000373983; ENSP00000363095; ENSG00000119401.
DR   Ensembl; ENST00000450136; ENSP00000408292; ENSG00000119401.
DR   GeneID; 22954; -.
DR   KEGG; hsa:22954; -.
DR   UCSC; uc004bjw.3; human.
DR   CTD; 22954; -.
DR   DisGeNET; 22954; -.
DR   GeneCards; TRIM32; -.
DR   GeneReviews; TRIM32; -.
DR   HGNC; HGNC:16380; TRIM32.
DR   HPA; HPA050060; -.
DR   MalaCards; TRIM32; -.
DR   MIM; 254110; phenotype.
DR   MIM; 602290; gene.
DR   MIM; 615988; phenotype.
DR   neXtProt; NX_Q13049; -.
DR   OpenTargets; ENSG00000119401; -.
DR   Orphanet; 1878; Autosomal recessive limb-girdle muscular dystrophy type 2H.
DR   Orphanet; 110; Bardet-Biedl syndrome.
DR   PharmGKB; PA38130; -.
DR   eggNOG; ENOG410ITFD; Eukaryota.
DR   eggNOG; ENOG410XRCH; LUCA.
DR   GeneTree; ENSGT00870000136512; -.
DR   HOGENOM; HOG000120114; -.
DR   HOVERGEN; HBG060344; -.
DR   InParanoid; Q13049; -.
DR   KO; K10607; -.
DR   OMA; EDFRCIT; -.
DR   OrthoDB; EOG091G0KUF; -.
DR   PhylomeDB; Q13049; -.
DR   TreeFam; TF331018; -.
DR   Reactome; R-HSA-3134975; Regulation of innate immune responses to cytosolic DNA.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q13049; -.
DR   UniPathway; UPA00143; -.
DR   EvolutionaryTrace; Q13049; -.
DR   GeneWiki; TRIM32; -.
DR   GenomeRNAi; 22954; -.
DR   PRO; PR:Q13049; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000119401; -.
DR   CleanEx; HS_TRIM32; -.
DR   ExpressionAtlas; Q13049; baseline and differential.
DR   Genevisible; Q13049; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:BHF-UCL.
DR   GO; GO:0005863; C:striated muscle myosin thick filament; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0017022; F:myosin binding; ISS:BHF-UCL.
DR   GO; GO:0043621; F:protein self-association; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; ISS:BHF-UCL.
DR   GO; GO:0030957; F:Tat protein binding; TAS:BHF-UCL.
DR   GO; GO:0003713; F:transcription coactivator activity; TAS:ProtInc.
DR   GO; GO:0031369; F:translation initiation factor binding; ISS:BHF-UCL.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:BHF-UCL.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0007014; P:actin ubiquitination; IEA:Ensembl.
DR   GO; GO:0061564; P:axon development; IEA:Ensembl.
DR   GO; GO:0045444; P:fat cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; IEA:Ensembl.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; ISS:BHF-UCL.
DR   GO; GO:1902230; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage; IDA:BHF-UCL.
DR   GO; GO:1902187; P:negative regulation of viral release from host cell; IDA:UniProtKB.
DR   GO; GO:0032897; P:negative regulation of viral transcription; IDA:UniProtKB.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IDA:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:2000147; P:positive regulation of cell motility; ISS:BHF-UCL.
DR   GO; GO:1903886; P:positive regulation of chemokine (C-C motif) ligand 20 production; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:1903883; P:positive regulation of interleukin-17-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0050769; P:positive regulation of neurogenesis; ISS:BHF-UCL.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:BHF-UCL.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; ISS:BHF-UCL.
DR   GO; GO:0045862; P:positive regulation of proteolysis; IDA:BHF-UCL.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0051155; P:positive regulation of striated muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:1903265; P:positive regulation of tumor necrosis factor-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:BHF-UCL.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:BHF-UCL.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0032479; P:regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0034612; P:response to tumor necrosis factor; ISS:BHF-UCL.
DR   GO; GO:0009411; P:response to UV; ISS:BHF-UCL.
DR   GO; GO:0001894; P:tissue homeostasis; IEA:Ensembl.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 2.120.10.30; -; 2.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR011042; 6-blade_b-propeller_TolB-like.
DR   InterPro; IPR001258; NHL_repeat.
DR   InterPro; IPR013017; NHL_repeat_subgr.
DR   InterPro; IPR033569; TRIM32.
DR   InterPro; IPR027370; Znf-RING_LisH.
DR   InterPro; IPR000315; Znf_B-box.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR24103:SF430; PTHR24103:SF430; 1.
DR   Pfam; PF01436; NHL; 3.
DR   Pfam; PF13445; zf-RING_UBOX; 1.
DR   SMART; SM00336; BBOX; 1.
DR   SMART; SM00184; RING; 1.
DR   PROSITE; PS51125; NHL; 5.
DR   PROSITE; PS50119; ZF_BBOX; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Bardet-Biedl syndrome; Ciliopathy;
KW   Coiled coil; Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Limb-girdle muscular dystrophy; Mental retardation;
KW   Metal-binding; Obesity; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000269|Ref.4}.
FT   CHAIN         2    653       E3 ubiquitin-protein ligase TRIM32.
FT                                /FTId=PRO_0000056246.
FT   REPEAT      358    401       NHL 1.
FT   REPEAT      415    458       NHL 2.
FT   REPEAT      459    499       NHL 3.
FT   REPEAT      562    605       NHL 4.
FT   REPEAT      606    646       NHL 5.
FT   ZN_FING      20     65       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   ZN_FING     103    133       B box-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00024}.
FT   COILED      138    197       {ECO:0000255}.
FT   COMPBIAS      2      6       Poly-Ala.
FT   MOD_RES       2      2       N-acetylalanine. {ECO:0000269|Ref.4}.
FT   MOD_RES     328    328       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8CH72}.
FT   MOD_RES     335    335       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     339    339       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT     130    130       P -> S (in BBS11; dbSNP:rs111033571).
FT                                {ECO:0000269|PubMed:16606853}.
FT                                /FTId=VAR_038807.
FT   VARIANT     257    257       T -> R (in dbSNP:rs3747834).
FT                                /FTId=VAR_038808.
FT   VARIANT     299    299       R -> Q (in a patient with Bardet-Biedl
FT                                syndrome; unknown pathological
FT                                significance; dbSNP:rs766439806).
FT                                {ECO:0000269|PubMed:21344540}.
FT                                /FTId=VAR_066295.
FT   VARIANT     394    394       R -> H (in LGMD2H; dbSNP:rs121434447).
FT                                {ECO:0000269|PubMed:17994549}.
FT                                /FTId=VAR_042939.
FT   VARIANT     408    408       R -> C (in dbSNP:rs3747835).
FT                                /FTId=VAR_038809.
FT   VARIANT     487    487       D -> N (in LGMD2H; dbSNP:rs111033570).
FT                                {ECO:0000269|PubMed:11822024}.
FT                                /FTId=VAR_018725.
FT   VARIANT     588    588       Missing (in LGMD2H).
FT                                {ECO:0000269|PubMed:17994549}.
FT                                /FTId=VAR_042940.
FT   CONFLICT     27     27       F -> I (in Ref. 1; AAA86474).
FT                                {ECO:0000305}.
FT   HELIX        11     16       {ECO:0000244|PDB:5FEY}.
FT   TURN         21     23       {ECO:0000244|PDB:5FEY}.
FT   STRAND       34     36       {ECO:0000244|PDB:5FEY}.
FT   STRAND       38     40       {ECO:0000244|PDB:2CT2}.
FT   STRAND       42     44       {ECO:0000244|PDB:5FEY}.
FT   HELIX        45     51       {ECO:0000244|PDB:5FEY}.
FT   STRAND       62     64       {ECO:0000244|PDB:5FEY}.
FT   TURN         73     75       {ECO:0000244|PDB:2CT2}.
FT   STRAND       76     78       {ECO:0000244|PDB:2CT2}.
FT   HELIX        80     85       {ECO:0000244|PDB:5FEY}.
SQ   SEQUENCE   653 AA;  71989 MW;  D83B1595CA8378FD CRC64;
     MAAAAASHLN LDALREVLEC PICMESFTEE QLRPKLLHCG HTICRQCLEK LLASSINGVR
     CPFCSKITRI TSLTQLTDNL TVLKIIDTAG LSEAVGLLMC RSCGRRLPRQ FCRSCGLVLC
     EPCREADHQP PGHCTLPVKE AAEERRRDFG EKLTRLRELM GELQRRKAAL EGVSKDLQAR
     YKAVLQEYGH EERRVQDELA RSRKFFTGSL AEVEKSNSQV VEEQSYLLNI AEVQAVSRCD
     YFLAKIKQAD VALLEETADE EEPELTASLP RELTLQDVEL LKVGHVGPLQ IGQAVKKPRT
     VNVEDSWAME ATASAASTSV TFREMDMSPE EVVASPRASP AKQRGPEAAS NIQQCLFLKK
     MGAKGSTPGM FNLPVSLYVT SQGEVLVADR GNYRIQVFTR KGFLKEIRRS PSGIDSFVLS
     FLGADLPNLT PLSVAMNCQG LIGVTDSYDN SLKVYTLDGH CVACHRSQLS KPWGITALPS
     GQFVVTDVEG GKLWCFTVDR GSGVVKYSCL CSAVRPKFVT CDAEGTVYFT QGLGLNLENR
     QNEHHLEGGF SIGSVGPDGQ LGRQISHFFS ENEDFRCIAG MCVDARGDLI VADSSRKEIL
     HFPKGGGYSV LIREGLTCPV GIALTPKGQL LVLDCWDHCI KIYSYHLRRY STP
//
